Trial will assess precision therapeutic vaccine in oesophageal cancer
Infinitopes has announced that the first patient has been dosed with ITOP1, the company’s lead investigational therapeutic cancer vaccine candidate.
This marks the first clinical evaluation of Infinitopes’ Precision Immunomics platform, which combines large-scale immunopeptidomic antigen discovery with engineered viral vector technologies, to identify naturally presented tumour antigens capable of generating durable anti-tumour T-cell responses.
The VISTA study (Vaccination with ITOP1 in resectable oesophageal adenocarcinoma to evaluate Safety, Tolerability and Anti-tumour activity) is a Phase I/IIa clinical trial conducted in partnership with the University of Oxford.
The study will evaluate ITOP1 in patients with newly diagnosed, surgically resectable oesophageal and gastro-oesophageal junction adenocarcinoma (OAC).
Unlike therapeutic vaccination approaches after surgery, VISTA investigates early treatment, while the primary tumour remains in situ. This is designed to test whether earlier immune priming, in the presence of the patient’s tumour antigens, can generate stronger anti-tumour T-cell responses alongside standard-of-care treatment.
Current standard-of-care for resectable OAC consists of neoadjuvant FLOT / durvalumab chemoimmunotherapy, surgery, and adjuvant chemoimmunotherapy. In the VISTA protocol, ITOP1 is administered between chemoimmunotherapy and surgery, both before and after oesophagectomy, allowing investigators to evaluate vaccine-induced immune responses throughout first-line treatment.
Professor Mark Middleton, Chief Investigator, VISTA Trial; Head of the Department of Oncology, University of Oxford; Consultant Medical Oncologist, Oxford University Hospitals NHS Foundation Trust, commented: “The first patient dosed in VISTA is an important landmark for our programme and for the wider field of therapeutic cancer vaccines. The neoadjuvant setting provides a fantastic opportunity to study immune responses while the patient’s primary tumour is still there. VISTA is designed to determine if this approach safely generates meaningful anti-tumour immunity and can delay recurrence after standard treatment and surgery.”
The Phase I study will recruit eight participants, before continuing into the placebo-controlled Phase IIa stage enrolling an additional 52 participants.
